Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 12, 2005, Pages 3980-3990

  Maring, Clarence J ^a,c   Stoll, Vincent S ^a   Zhao, Chen ^a   Sun, Minghua ^a   Krueger, Allan C ^a   Stewart, Kent D ^a   Madigan, Darold L ^a   Kati, Warren M ^a   Xu, Yibo ^a   Carrick, Robert J ^a   Montgomery, Debra A ^a   Kempf Grote, Anita ^a   Marsh, Kennan C ^a   Molla, Akhteruzzaman ^a   Steffy, Kevin R ^d   Sham, Hing L ^a   Laver, W Graeme ^b   Gu, Yu Gui ^a   Kempf, Dale J ^a   Kohlbrenner, William E ^a  

^a ABBOTT LABORATORIES   (United States)

^b Biology and Environment   (Australia)

^c AP52N ^*  (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMINE; ESTER; OSELTAMIVIR; PERAMIVIR; PRODRUG; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG STRUCTURE; HYBRIDIZATION; HYDROGEN BOND; HYDROPHOBICITY; PROTEIN CONFORMATION; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; CRYSTALLOGRAPHY, X-RAY; HYDROPHOBICITY; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MODELS, MOLECULAR; NEURAMINIDASE; PYRROLIDINES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20444378860     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049276y     Document Type: Article

References (35)

1. Nicholson, K. G.; Wood J.; M.; Zambon, M. Influenza. Lancet 2003, 362, 1733-1745.
2. Snacken, R. Pandemic planning. Vaccine 2002, 20, S88-S90.
3. Neuzil, K. M.; Griffin, M. R.; Schaffner, W. Influenza vaccine: Issues and opportunities. Infect. Dis. Clin. N. Am. 2001, 15, 123-141, ix.
4. Regan, S. F.; Fowler, C. Influenza. Past, present, and future. J. Gerontol. Nursing 2002, 28, 30-37.
5. Noyola, D. E. Neuraminidase inhibitors in pediatric patients: Potential place in influenza therapy. Pediatr. Drugs 2003, 5, 125-131.
6. Oxford, J. S.; Novelli, P.; Sefton, A.; Lambkin, R. New millennium antivirals against pandemic and epidemic influenza: The neuraminidase inhibitors. Antiviral Chem. Chemother. 2002, 13, 205-217
7. von Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication [comment]. Nature 1993, 363, 418-423.
8. Wade, R. C. 'Flu' and structure-based drug design. Structure 1997, 5, 1139-1145.
9. Cooper, N. J.; Button, A. J.; Abrams, K. R.; Wailoo, A.; Turner, D., et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: Systematic review and meta-analyses of randomised controlled trials. Br. Med. J. 2003, 326, 1235.
10. Kirkbride, H. A.; Watson, J. Review of the use of neuraminidase inhibitors for prophylaxis of influenza [review]. Communicable Dis. Public Health 6 (2), 123-7.
11. Oxford, J. S.; Bossuyt, S.; Balasingam, S.; Mann., A.; Novelli, P.; Lambkin, R. Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clin. Microbiol. 2003, 9, 1-14.
12. Barnard, D. L. RWJ-270201 BioCryst Pharmaceuticals/Johnson & Johnson. Curr. Opin. Invest. Drugs 2000, 1, 421-424.
13. Young, D.; Fowler, C.; Bush, K. RWJ-270201 (BCX-1812): A novel neuraminidase inhibitor for influenza. Philos. Trans. R. Soc. London Ser. B 2001, 356, 1905-1913.
14. Kim, C. U.; Chen, X.; Mendel, D. B. Neuraminidase inhibitors as anti-influenza virus agents. Antiviral Chem. Chemother. 1999, 10, 141-154.
15. Lew, W.; Chen, X.; Kim, C. U. Discovery and development of GS 4104 (oseltamivir): An orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 2000, 7, 663-672.
16. Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A., et al. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43, 3482-3486.
17. Driguez, P. A.; Barrere, B.; Quash, G.; Doutheau, A. Synthesis of transition-state analogues as potential inhibitors of sialidase from Influenza virus. Carbohydr. Res. 1994, 262, 297-310.
18. McKimm-Breschkin, J. L. Resistance of influenza viruses to neuraminidase inhibitors - A review. Antiviral Res. 2000, 47, 1-17.
19. Gubareva, L. V.; Webster, R. G.; Hayden, F. G. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 2002, 53, 47-61.
20. Smee, D. F.; Sidwell, R. W.; Morrison, A. C.; Bailey, K. W.; Baum, E. Z.; et al. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. Antiviral Res. 2001, 52, 251-259.
21. Stoll, V.; Stewart, K. D.; Maring, C. J.; Muchmore, S.; Giranda, V. et al. Influenza neuraminidase inhibitors: Structure-based design of a novel inhibitor series. Biochemistry 2003, 42, 718-727.
22. Gu, Y. G.; Xu, Y.; Krueger, A. C.; Madigan, D.; Sham, H., L. 1,3-Dipolar cycloaddition reactions of ester-stabilized azomethine ylides with acrolein: A one-pot regio- and stereoselective synthesis of N-substituted 4-formyl-5-vinyl proline carboxylates. Tetrahedron Lett. 2002, 43, 955-957.
23. Varghese, J. N.; Epa, V. C.; Colman, P. M. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci. 1995, 4, 1081-1087.
24. Kati, W. M.; Montgomery, D.; Maring, C.; Stoll, V. S.; Giranda, V., et al. Novel alpha- and beta-amino acid inhibitors of influenza virus neuraminidase. Antimicrob. Agents Chemother. 2001, 45, 2563-2570.
25. Kati, W. M.; Saldivar, A.; Maring, C. J.; Madigan, D. L.; Gu, Y.-G. et al. Pitfalls in the Biochemical Evaluation of Influenza Neuraminidase Inhibitors. Antiviral Res. 2000, 46, A59.
26. Smith, B. J.; Colman, P. M.; Von Itzstein, M.; Danylec, B.; Varghese, J. N. Analysis of inhibitor binding in influenza virus neuraminidase. Protein Sci. 2001, 10, 689-696.
27. Bantia, S.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Andries, K., et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 2001, 45, 1162-1167.
28. Gubareva, L. V.; Webster, R. G.; Hayden, F. G. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 2001, 45, 3403-3408.
29. Hanessian, S.; Wang, J.; Montgomery, D.; Stoll, V.; Stewart, K. D. Kati, W.; Maring, C.; Kempf, D.; Hutchins, C.; Laver, W. G.; Design, synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm. Bioorg. Med. Chem. Lett. 2002, 12, 3425-3429.
30. Kati, W. M.; Montgomery, D.; Carrick, R.; Gubareva, L.; Maring, C., et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strahl influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. 2002, 46, 1014-1021.
31. Molla, A.; Kati, W.; Carrick, R.; Steffy, K.; Shi, Y., et al. In Vitro Selection and Characterization of Influenza A (A/N9) Virus Variants Resistant to a Novel Neuraminidase Inhibitor, A-315675. J. Virol. 2002, 76, 5380-5386.
32. Laver, W. G.; Coleman, P. M., Webster, R. G.; Hinshaw, V. S.; Air, G. M. Virology 1984, 137, 314-323.
33. Otwinowski, Z.; Minor, W. Methods Enzymol. 1997, 276, 307-326.
34. Brunger, A. T.; Adams, P. D., Clore, G. M.; DeLano, W. L.; Gros, P., Grosse-Kunstleve, R. W.; Ralf W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 905.
35. Badger, J.; Berard, D.; Kumar, R. A.; Szalma, S.; Yip, P.; Griesinger, C.; Junker, J. 1999 CNX Software Manual, Molecular Simulations, Inc., San Diego, CA.